Company profile for Viela Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Our team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. We believe that our appr...
Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. Our team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. We believe that our approach – which targets the underlying molecular pathogenesis of the disease – enables us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One MedImmune Way First Floor, Area Two Gaithersburg, MD 20878
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761142

FDA
03 Apr 2025

https://endpts.com/beigene-co-founder-and-ex-viela-bio-bd-leader-snag-200m-for-age-related-biotech-with-arch-jumping-in/

Kyle LaHucik ENDPTS
02 Aug 2022

https://www.ema.europa.eu/en/documents/overview/uplizna-epar-medicine-overview_en.pdf

EMA
19 May 2022

https://www.fiercepharma.com/pharma/insider-trading-2-pharma-m-a-deals-made-former-goldman-sachs-compliance-officer-more-than

Kevin Dunleavy FIERCEPHARMA
01 Oct 2021

https://www.biospace.com/article/releases/viela-bio-announces-additional-positive-results-with-uplizna-inebilizumab-cdon-in-patients-with-neuromyelitis-optica-spectrum-disorder-at-the-actrims-2021-forum/

BIOSPACE
26 Feb 2021

https://www.globenewswire.com/fr/news-release/2021/02/25/2182496/0/en/Viela-Bio-Announces-Additional-Positive-Results-with-UPLIZNA-inebilizumab-cdon-in-Patients-with-Neuromyelitis-Optica-Spectrum-Disorder-at-the-ACTRIMS-2021-Forum.html

GLOBENEWSWIRE
25 Feb 2021

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty